20 research outputs found
Interferon alpha2 in the treatment of hematological malignancies. status and perspectives
No full textA new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms
No full textInterferon alfa in the treatment of philadelphia-negative chronic myeloproliferative neoplasms
No full textCombination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
Get PDFWe report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy
Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives
No full textCorrigendum to “Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera” [Leuk. Res. Rep. 3 (2) (2014) 73–75]
Get PDFSustained major molecular response on interferon alpha-2b in two patients with polycythemia vera
No full text
Increase in circulating CD4CD25Foxp3 T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α
No full textGene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis
No full text
